Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatr Infect Dis J. 2013 Mar;32(3):278-83. doi: 10.1097/INF.0b013e318275328f.

PMID:
23014356
2.

Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatrics. 2010 Feb;125(2):e208-13. doi: 10.1542/peds.2009-1246. Epub 2010 Jan 25.

PMID:
20100757
3.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).

Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M.

Hum Vaccin. 2011 May;7(5):563-8. Epub 2011 May 1.

PMID:
21441783
4.

Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013.

Payne DC, Selvarangan R, Azimi PH, Boom JA, Englund JA, Staat MA, Halasa NB, Weinberg GA, Szilagyi PG, Chappell J, McNeal M, Klein EJ, Sahni LC, Johnston SH, Harrison CJ, Baker CJ, Bernstein DI, Moffatt ME, Tate JE, Mijatovic-Rustempasic S, Esona MD, Wikswo ME, Curns AT, Sulemana I, Bowen MD, Gentsch JR, Parashar UD.

Clin Infect Dis. 2015 Dec 15;61(12):1792-9. doi: 10.1093/cid/civ872. Epub 2015 Oct 8.

PMID:
26449565
5.

Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice.

Bégué RE, Perrin K.

Pediatrics. 2010 Jul;126(1):e40-5. doi: 10.1542/peds.2009-2069. Epub 2010 Jun 29.

PMID:
20587671
6.

Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule.

Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, Akikusa JD, Kelly JJ, Kirkwood CD.

Pediatr Infect Dis J. 2011 Jan;30(1 Suppl):S25-9. doi: 10.1097/INF.0b013e3181fefdee. Erratum in: Pediatr Infect Dis J. 2011 Oct; 30(10):916.

PMID:
21183837
7.

Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.

Leshem E, Givon-Lavi N, Tate JE, Greenberg D, Parashar UD, Dagan R.

Clin Infect Dis. 2016 May 1;62 Suppl 2:S155-60. doi: 10.1093/cid/civ1012.

PMID:
27059350
8.

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.

Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, Patel MM, Baker CJ, Parashar UD.

Pediatrics. 2010 Feb;125(2):e199-207. doi: 10.1542/peds.2009-1021. Epub 2010 Jan 18.

PMID:
20083525
9.

Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine.

Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM, Patel MM, Baggs JM, Parashar UD.

Pediatrics. 2009 Mar;123(3):744-9. doi: 10.1542/peds.2008-1200.

PMID:
19254997
10.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.

Vesikari T, Karvonen A, Ferrante SA, Ciarlet M.

Eur J Pediatr. 2010 Nov;169(11):1379-86. doi: 10.1007/s00431-010-1242-3. Epub 2010 Jun 18.

11.

Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011.

Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ, Selvarangan R, Azimi PH, Harrison C, Moffatt M, Johnston SH, Sahni LC, Baker CJ, Rench MA, Donauer S, McNeal M, Chappell J, Weinberg GA, Tasslimi A, Tate JE, Wikswo M, Curns AT, Sulemana I, Mijatovic-Rustempasic S, Esona MD, Bowen MD, Gentsch JR, Parashar UD.

Clin Infect Dis. 2013 Jul;57(1):13-20. doi: 10.1093/cid/cit164. Epub 2013 Mar 13.

12.
13.

Cost effectiveness of a pentavalent rotavirus vaccine in Oman.

Al Awaidy ST, Gebremeskel BG, Al Obeidani I, Al Baqlani S, Haddadin W, O'Brien MA.

BMC Infect Dis. 2014 Jun 17;14:334. doi: 10.1186/1471-2334-14-334.

14.

Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs.

Donauer S, Payne DC, Edwards KM, Szilagyi PG, Hornung RW, Weinberg GA, Chappell J, Hall CB, Parashar UD, Staat MA.

Vaccine. 2013 May 31;31(24):2692-7. doi: 10.1016/j.vaccine.2013.03.072. Epub 2013 Apr 12.

15.

Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries.

El Khoury AC, Mast TC, Ciarlet M, Markson LE, Goveia MG.

Hum Vaccin. 2011 May;7(5):506-10. Epub 2011 May 1.

16.

Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua.

Mast TC, Khawaja S, Espinoza F, Paniagua M, Del Carmen LP, Cardellino A, Sánchez E.

Pediatr Infect Dis J. 2011 Nov;30(11):e209-15. doi: 10.1097/INF.0b013e31822a8527.

PMID:
21768920
17.

Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia.

Field EJ, Vally H, Grimwood K, Lambert SB.

Pediatrics. 2010 Sep;126(3):e506-12. doi: 10.1542/peds.2010-0443. Epub 2010 Aug 23.

PMID:
20732946
18.

Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States.

Weycker D, Atwood MA, Standaert B, Krishnarajah G.

Hum Vaccin Immunother. 2014;10(7):2032-8. doi: 10.4161/hv.28689.

19.

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.

Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M.

Pediatr Infect Dis J. 2010 Oct;29(10):957-63. doi: 10.1097/INF.0b013e3181e28e6e.

PMID:
20442684
20.

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).

Itzler R, Koch G, Matson DO, Gothefors L, Van Damme P, Dinubile MJ, Heaton PM.

BMC Pediatr. 2010 Jun 11;10:42. doi: 10.1186/1471-2431-10-42.

Supplemental Content

Support Center